Syngen BiotechLtd (8279) Stock Overview
Engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
8279 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Syngen Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$85.00 |
| 52 Week High | NT$141.00 |
| 52 Week Low | NT$83.60 |
| Beta | 0.15 |
| 1 Month Change | -3.95% |
| 3 Month Change | -12.82% |
| 1 Year Change | -32.00% |
| 3 Year Change | -50.29% |
| 5 Year Change | -5.56% |
| Change since IPO | 761.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8279 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -2.5% | 2.1% | -2.5% |
| 1Y | -32.0% | -25.7% | 85.0% |
Return vs Industry: 8279 underperformed the TW Pharmaceuticals industry which returned -25.7% over the past year.
Return vs Market: 8279 underperformed the TW Market which returned 85% over the past year.
Price Volatility
| 8279 volatility | |
|---|---|
| 8279 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in TW Market | 11.9% |
| 10% least volatile stocks in TW Market | 2.7% |
Stable Share Price: 8279 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 8279's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Wei Chen | www.syngen.com.tw |
Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, and capsules; and elderly health care, beauty enhancing supplements, probiotics, digestive aids and enzymes, weight loss and nutrition, immune acid, fitness and energy, and pet supplement products. It also provides science-based and bio active pharmaceutical ingredients, including Oraltics, a lactobacillus fermentum SG-A95; IMMUPHYLA, a heat-killed lactobacillus paracasei LCW23; V3, a lactobacillus fermentum; ST4SanTex, a streptococcus thermophilus; GUARDSPO, a bacillus coagulans; benefiGANO, a ganoderma lucidum, EXPUNERGY, a hirsutella sinensis mycelium; and BIOJOVIAL, a lactobacillus brevis.
Syngen Biotech Co.,Ltd. Fundamentals Summary
| 8279 fundamental statistics | |
|---|---|
| Market cap | NT$2.30b |
| Earnings (TTM) | NT$226.03m |
| Revenue (TTM) | NT$2.05b |
Is 8279 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8279 income statement (TTM) | |
|---|---|
| Revenue | NT$2.05b |
| Cost of Revenue | NT$1.40b |
| Gross Profit | NT$653.46m |
| Other Expenses | NT$427.44m |
| Earnings | NT$226.03m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.34 |
| Gross Margin | 31.83% |
| Net Profit Margin | 11.01% |
| Debt/Equity Ratio | 0% |
How did 8279 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 15:09 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syngen Biotech Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Hsiu Chi Lin | Masterlink Securities Investment Advisory |